Qubigen (@qubigen) header
Qubigen (@qubigen) profile picture

Intelligent Drug Design. A global federated AI system and computational toolbox for designing novel targeted medicines

Joined November 2024
Photo by Qubigen (@qubigen)Photo by Qubigen (@qubigen)Photo by Qubigen (@qubigen)Photo by Qubigen (@qubigen)Photo by Qubigen (@qubigen)Photo by Qubigen (@qubigen)Photo by Qubigen (@qubigen)Photo by Qubigen (@qubigen)Photo by Qubigen (@qubigen)Photo by Qubigen (@qubigen)
Following our Gold win in the Medical category at the 2026 AFR BOSS Most Innovative Companies Awards, we broke down why solving this data-sovereignty bottleneck is essential for the future of drug discovery 🔗Link in the comments below 👇
2
1
2
24
Qubigen won Gold in Medical at the 2026 AFR BOSS Most Innovative Companies Awards. While the big agentic AI and frontier lab deals (Xaira’s X-Scientist, OpenAI’s Orchestra Bio acquisition, AZ–insitro) get the headlines, the hard constraint remains the same: most models still need either public data or private project data that leaves the lab.
2
1
97
Congrats to @DrJMMHall and the @QubigenOps @qubigen team for winning Gold in the AFR Most Innovative Companies 2026 Awards for their novel AI platform which enables AI for drug design without compromising stakeholder privacy or intellectual property. afr.com/life-and-luxury/heal…
1
2
2
79
“Winning gold in the Medical category of the Financial Review BOSS Most Innovative Companies awards, Qubigen’s AI tool can learn from a trove of pharmaceutical lab investigations, all without copying or sharing the data.” See link to the full article in the comments below 👇
1
1
1
67
🚨 🚨 On Wednesday Night, @qubigen was named the Gold winner in the Medical category of The Australian Financial Review AFR BOSS Most Innovative Companies Awards, taking out the top spot of this National competition! 🏆 This recognition reflects the groundbreaking work our team is doing to pioneer decentralised intelligence in drug discovery: building a platform that allows research labs to learn from their own high-value results without ever compromising, copying, or sharing raw data. A huge congratulations 🥂 and thank you to our all-star team who made this possible: Sonya Diakiw (CSO), A/Prof Jun Zeng FRACI (CIO), Andrew Murphy (CTO), David Brooks (Operations Manager), Dr Tuc Van Nguyen (Senior Machine Learning Engineer), and Joshua Spender (Senior Software Engineer). Special thanks to our board of directors for their continued support and backing, SYNthesis BioVentures, Prof. Andrew Wilks , Dr Amir Zalcenstein, Dr Fabio Turatti, James Roche, Chair Dr Michelle Perugini and our Corp Sec Rosemarie Singson. Thank you to our advisors Matt Oristano, Trevor Thompson, Eric Hayes, and finally, to all the research and commercial partners who have worked with us and continue to collaborate with us on live projects.
2
2
2
150
BIO 2026 Debrief: AI for drug discovery must be domain-specific, privacy-preserving and deployed in a way that enables organizations to retain full control of their data and intellectual property. qubigen.com/post/bio-2026-de…
2
1
2
140
Qubigen is pleased to share encouraging progress from its ongoing collaboration with QIMR Berghofer. linkedin.com/posts/qubigen-i…
1
1
2
129
Qubigen’s recent study on tailored federated AI for blood-brain-barrier permeability prediction has now been featured by Diagnostics World News in an article exploring why specialized AI systems are outperforming generic foundation models in life sciences. diagnosticsworldnews.com/new…
🤖 Made with AI
2
1
2
132
Qubigen is pleased to report on a research collaboration with Dr. Srinivas Viswanathan and his team at Dana-Farber Cancer Institute. The project focuses on the discovery of novel small-molecule candidates for a rare and aggressive type of kidney cancer. qubigen.com/post/qubigen-col…
2
1
3
128
At Qubigen, we investigated whether our AI Engine, tailored to client-specific data using our Federated AI platform, could outperform generalist models for predicting BBB permeability. qubigen.com/post/tailored-ai…
2
1
3
119
Qubigen is pleased to announce the launch of a new collaborative Federated AI drug design project focused on the development of novel antiviral small molecules for emerging infectious diseases. qubigen.com/post/qubigen-lau…
2
1
3
177
Qubigen is pleased to announce a new collaboration with Viva Biotech, a global leader in AI-enabled drug discovery, to explore failed (‘dark’) reaction data. qubigen.com/post/qubigen-ann…
1
2
1
3
356
Federated AI Engines for drug design enable secure collaboration, transcending institutional data firewalls. Qubigen's FedAIDD can leverage global data without actually moving or seeing it, to build the most intelligent, secure, disease-agnostic AI engines in drug design.
1
1
4
88
. @qubigen is heading to San Francisco for J.P. Morgan Healthcare Week 2026 (11–15 January)! 🇺🇸 🇦🇺🐨 Proud to be part of the Australian Biotech Delegation, supported by Global Victoria. We’ll be actively partnering at BIO One-on-One, ABD Capital Connect sessions, and around Union Square. Our Federated AI/ML platform is already accelerating drug design for pharma and CRO partners, collapsing hit-to-lead from years to weeks, securely and at fraction of the cost. If you’re attending and interested in AI-enabled drug design or Series A discussions, let’s connect! Reach me via BIO Partnering, ABD, or DM here. Excited to build new bridges Down Under in the Bay Area.
2
2
4
217
In just over twelve months, Qubigen has evolved from an innovative idea into a validated, capital-efficient drug design platform, demonstrating that secure, Federated AI can deliver real scientific progress, commercial traction, and scalable value. qubigen.com/post/one-year-of…
1
1
1
55